Pure Global
NCT06099184

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME)
EyePoint Pharmaceuticals, Inc.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetic Macular Edema
Drug/Device/Intervention
EYP-1901
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
EyePoint Pharmaceuticals, Inc.
Timeline & enrollment
Phase
Phase 2
Start date
Jan 15, 2024
End date
Jan 15, 2025
Enrollment
25 participants
Primary outcome

Time to first supplemental aflibercept injection following EYP-1901 dose at Baseline vs Aflibercept

Summary

A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of
 two doses of the EYP-1901 intravitreal insert compared to aflibercept

ICD-10 classifications
Diabetic retinopathyOther specified diabetes mellitus with ophthalmic complicationsUnspecified diabetes mellitus with ophthalmic complicationsDiabetic cataractType 2 diabetes mellitus with ophthalmic complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06099184
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06099184 through Pure Global AI's free database. This Phase 2 trial is sponsored by EyePoint Pharmaceuticals, Inc. and is currently Not yet recruiting. The study focuses on Diabetic Macular Edema. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.